<!DOCTYPE  html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en"><head><meta http-equiv="Content-Type" content="text/html; charset=utf-8"/><title>12 Rectal cancer</title><link href="navigation.css" rel="stylesheet" type="text/css"/><link href="document.css" rel="stylesheet" type="text/css"/></head><body><p class="top_nav"><a href="part17.htm">&lt; Назад</a><span> | </span><a href="../index.html">Содержимое</a><span> | </span><a href="part19.htm">Далее &gt;</a></p><p style="padding-top: 3pt;padding-left: 55pt;text-indent: 0pt;text-align: left;"><a href="part5.htm#bookmark17" class="s95" name="bookmark55">Chapter 12</a><a name="bookmark56">&zwnj;</a></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 55pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="374" height="1" alt="image" src="Image_174.png"/></span></p><p style="padding-top: 4pt;padding-left: 55pt;text-indent: 0pt;text-align: left;"><h2 href="#bookmark17">Rectal cancer</h2></p><p class="s5" style="padding-top: 10pt;padding-left: 53pt;text-indent: 0pt;text-align: left;">Vivek Misra and rohit Kochhar</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s96" style="padding-top: 13pt;padding-left: 11pt;text-indent: 0pt;text-align: left;">12.1 <span class="h4">Clinical background</span></p><p style="padding-top: 4pt;padding-left: 11pt;text-indent: 0pt;line-height: 94%;text-align: justify;">Colorectal cancer is the fourth most common cancer in the UK. Of the approximately 40,000 new cases annually, a quarter to a third are located in the rectum. Rectal cancer is more common in men and the highest rate is in the 85–89 years age group for both males and females. Adenocarcinomas account for over 90% of tumours, the remainder consist of squamous carcinomas, carcinoid, lymphoma, melanoma, and gastrointes- tinal stromal tumours. Presentation includes rectal bleeding, change in bowel habit, frequency of defaecation, tenesmus, rectal fullness, and pelvic pain. With the intro- duction of bowel screening in the UK for people between the ages of 50 and 74 years, asymptomatic patients are increasingly diagnosed. Distant spread most commonly occurs to the liver, lung, and peritoneum. Metastases are less commonly seen in the bones, brain, and other areas.</p><p style="padding-left: 11pt;text-indent: 8pt;line-height: 94%;text-align: justify;">Advances in surgical technique and more accurate radiotherapy planning and de- livery have improved rectal cancer outcome. Anterior resection combined with total mesorectal excision (TME) has become the standard surgical procedure, facilitating the radial clearance of the primary tumour, mesorectal tissue, and associated vas- cular, lymphatic, and perineural deposits, thus improving local recurrence rates. Abdominoperineal resection is now reserved for low rectal tumours when sphincter integrity cannot be preserved.</p><p style="padding-left: 11pt;text-indent: 8pt;line-height: 94%;text-align: justify;">In the UK, preoperative radiotherapy (RT) or chemoradiotherapy (CRT) prior to surgery is recommended to reduce the risk of local relapse or to downstage inoperable disease. Recent non-randomized evidence suggests that a non-operative approach for patients with a complete clinical response following neo-adjuvant CRT may be safe, with reduced long-term morbidity and preservation of sphincter function.<span class="s22">1 </span>This ap- proach is currently the subject of randomized controlled trials. In patients otherwise unfit for neoadjuvant CRT and with localized rectal cancers, radiotherapy alone may provide meaningful downstaging of the disease and allow surgery in a significant pro- portion of patients.</p><p style="padding-left: 11pt;text-indent: 8pt;line-height: 94%;text-align: justify;">Accurate staging is essential to ensure the correct therapeutic approach is under- taken. Imaging plays a pivotal role in defining which patients may benefit from rad- ical surgery, selecting the most relevant surgical procedure, and identifying patients in whom a postoperative margin (R0) resection is not possible with surgery alone, and for whom preoperative RT or CRT may be appropriate.</p><p class="s96" style="padding-top: 4pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">12.2 <span class="h4">Diagnosis and staging</span></p><p class="s97" style="padding-top: 6pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">12.2.1 <span class="s29">Diagnosis</span></p><p style="padding-top: 3pt;padding-left: 5pt;text-indent: 0pt;line-height: 94%;text-align: justify;">Rectal cancer is most commonly diagnosed by lower gastrointestinal endoscopy (fibreoptic colonoscopy) and biopsy, although imaging is an alternative where com- puted tomography (CT) colonography has superseded barium enema for diagnosis.<span class="s22">2 </span>The capability of CT to reconstruct images into dynamic navigable 3D views of the colon simulating fibreoptic colonoscopy has popularized the technique. A systematic review has suggested that CT colonography has high average sensitivity and specifi- city for large and medium colorectal polyps (&gt;10 mm and 6–10 mm respectively), and excellent sensitivity for cancer in the symptomatic population, with &gt;96% of cancers detected.</p><p class="s97" style="padding-top: 10pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">12.2.2 <span class="s29">Staging</span></p><p style="padding-top: 3pt;padding-left: 5pt;text-indent: 0pt;line-height: 94%;text-align: justify;">A clear understanding of the anatomy (Figure 12.1) and pathway of spread is im- portant for accurate staging. A commonly used definition for rectal cancer is an</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 53pt;text-indent: 0pt;text-align: left;"><span><img width="297" height="297" alt="image" src="Image_175.gif"/></span></p><p class="s24" style="padding-top: 7pt;padding-left: 5pt;text-indent: 0pt;line-height: 114%;text-align: left;">Fig. 12.1 <span class="s52">sagittal T2-weighted Mr image demonstrating the divisions of the rectum extending from s3 to the level of the levator plate. The anorectal junction is identified by the pubococcygeal line (solid bold line) extending from inferior tip of symphysis to the last coccygeal joint. The lower rectum (round dotted line) extends from the anorectal junction to 6 cm from the anal verge. The mid rectum (short dash line) extends to 10 cm from the verge and the upper rectum (long dash line) extends to s3. anteriorly, the peritonealized surface of the upper rectum can be identified (arrowheads).</span></p><p style="padding-top: 4pt;padding-left: 11pt;text-indent: 0pt;line-height: 94%;text-align: justify;">adenocarcinoma with a distal margin ≤15 cm from the anal verge, as measured by rigid sigmoidoscopy. ‘Low’ rectal cancers are those with the lower edge, at or below the origin of the levators at the pelvic side-wall on magnetic resonance imaging (MRI), which usually corresponds to within 6 cm of the anal verge. Once a tumour has pene- trated through the muscularis propria, growth can extend deep into perirectal fat. Below the supporting structures of the anus, tumour can extend into the ischiorectal fossa, a potential space around the anal canal and sphincter. Hence, there is a high risk of locoregional failure for low tumours. Lymphatic drainage to regional nodes is dependent on site. Mid-upper rectal tumours drain to perirectal nodes and along the superior rectal vessels to the inferior mesenteric vessels. Low-mid rectal tumours drain to perirectal nodes and along mid-rectal vessels to the internal iliac vessels. Most involved perirectal nodes within the mesorectum lie either at the level of, or within 5 cm proximal to, the primary tumour. Lateral pelvic lymph nodes (external iliac and obturator nodes) may be involved in 10–25% of patients with rectal cancer. As lateral pelvic and internal iliac nodes are not removed with a standard TME, there is risk of local recurrence at these sites with surgery alone. Venous drainage of the upper rectum is via the superior rectal vein to the inferior mesenteric vein and portal system, while drainage of the mid and lower rectum is to the iliac veins and inferior vena cava, thus metastases can develop either in the liver or lungs, depending on tumour site.</p><p style="padding-left: 19pt;text-indent: 0pt;line-height: 11pt;text-align: justify;">Accurate staging is essential for defining the most appropriate treatment strategy. The</p><p style="padding-left: 11pt;text-indent: 0pt;line-height: 94%;text-align: justify;">accepted standard for staging cancer is based on the Union for International Cancer Control (UICC) Tumour Node Metastasis (TNM) staging, currently in its eighth edition (Table 12.1), although Dukes’ classification also remains in use (Table 12.2). Staging should also address synchronous colonic cancers. Additional information be- yond TNM staging which is vital for treatment decisions is: (1) the relationship of the tumour to the potential circumferential resection margin (CRM) indicating the like- lihood of a clear R0; (2) the presence of extramural venous invasion (EMVI), a prog- nostic feature; and (3) the relationship of the tumour to the anal sphincter complex which defines whether sphincter-sparing surgery is possible for low rectal cancer, as well as the need for preoperative RT.</p><p style="padding-left: 11pt;text-indent: 8pt;line-height: 94%;text-align: justify;">MRI is the modality of choice for locoregional staging (Figure 12.2). T-staging accuracies ranging from 71% to 91% have been reported, although differentiation between T2 and early T3 tumours remains challenging due to desmoplasis and microscopic disease. MRI has also been validated prospectively (MERCURY) with an accuracy of 87% and specificity of 92% in predicting a clear CRM (&gt;1 mm).<span class="s22">3 </span>Patients with tumours that extend to within a small distance of the mesorectal fascia (e.g. 1 mm), that lie outside the mesorectum, or that extend inferiorly to the anorectal junction should be offered adjuvant RT. The distance of tumour to the CRM is also a prognostic factor for overall five-year survival.</p><p style="padding-left: 11pt;text-indent: 8pt;line-height: 94%;text-align: justify;">Extramural venous invasion (EMVI) is defined by the presence of tumour cells beyond the muscularis propria in endothelium-lined vessels. It is an important and independent risk factor for local and distant recurrence as well as reduced survival requiring treatment intensification.<span class="s22">4 </span>On MRI intermediate signal intensity tumour is seen invading or expanding a vessel. The invaded vessel has similar signal intensity to the tumour (Figure 12.2). EMVI is recorded as positive or negative and a note is made as to whether the involved vessels lie close to the mesorectal fascia.</p><p class="s24" style="padding-top: 5pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">Table 12.1 <span class="s52">TnM staging, eighth edition</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><table style="border-collapse:collapse;margin-left:5.6929pt" cellspacing="0"><tr style="height:15pt"><td style="width:323pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9" colspan="2"><p class="s26" style="padding-top: 2pt;text-indent: 0pt;text-align: left;">T primary tumour</p></td></tr><tr style="height:15pt"><td style="width:23pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;text-indent: 0pt;text-align: left;">TX</p></td><td style="width:300pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;padding-left: 9pt;text-indent: 0pt;text-align: left;">primary tumour cannot be assessed</p></td></tr><tr style="height:15pt"><td style="width:23pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;text-indent: 0pt;text-align: left;">T0</p></td><td style="width:300pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;padding-left: 9pt;text-indent: 0pt;text-align: left;">no evidence of primary tumour</p></td></tr><tr style="height:15pt"><td style="width:23pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;text-indent: 0pt;text-align: left;">Tis</p></td><td style="width:300pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;padding-left: 9pt;text-indent: 0pt;text-align: left;">Carcinoma <i>in situ</i>: invasion of lamina propria<span class="s116">a</span></p></td></tr><tr style="height:15pt"><td style="width:23pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;text-indent: 0pt;text-align: left;">T1</p></td><td style="width:300pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;padding-left: 9pt;text-indent: 0pt;text-align: left;">Tumour invades submucosa</p></td></tr><tr style="height:15pt"><td style="width:23pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;text-indent: 0pt;text-align: left;">T2</p></td><td style="width:300pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;padding-left: 9pt;text-indent: 0pt;text-align: left;">Tumour invades muscularis propria</p></td></tr><tr style="height:15pt"><td style="width:23pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;text-indent: 0pt;text-align: left;">T3</p></td><td style="width:300pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;padding-left: 9pt;text-indent: 0pt;text-align: left;">Tumour invades subserosa or into non-peritonealized pericolic or perirectal tissues</p></td></tr><tr style="height:26pt"><td style="width:23pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;text-indent: 0pt;text-align: left;">T4</p></td><td style="width:300pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;padding-left: 9pt;text-indent: 0pt;line-height: 111%;text-align: left;">Tumour directly invades other organs or structures<span class="s116">b,c,d </span>and/or perforates visceral peritoneum</p></td></tr><tr style="height:15pt"><td style="width:23pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;text-indent: 0pt;text-align: left;">T4a</p></td><td style="width:300pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;padding-left: 9pt;text-indent: 0pt;text-align: left;">Tumour perforates visceral peritoneum</p></td></tr><tr style="height:15pt"><td style="width:23pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;text-indent: 0pt;text-align: left;">T4b</p></td><td style="width:300pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;padding-left: 9pt;text-indent: 0pt;text-align: left;">Tumour directly invades other organs or structures</p></td></tr><tr style="height:107pt"><td style="width:323pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9" colspan="2"><p class="s106" style="padding-top: 2pt;text-indent: 0pt;text-align: left;">notes</p><p class="s117" style="padding-top: 3pt;padding-right: 8pt;text-indent: 0pt;line-height: 109%;text-align: left;">a <span class="s118">Tis includes cancer cells confined within the mucosal lamina propria (intramucosal) with no extension through the muscularis mucosae into the submucosa.</span></p><p class="s117" style="padding-top: 3pt;text-indent: 0pt;text-align: left;">b <span class="s118">invades through to visceral peritoneum to involve the surface.</span></p><p class="s117" style="padding-top: 3pt;text-indent: 0pt;line-height: 109%;text-align: left;">c <span class="s118">Direct invasion in T4b includes invasion of other organs or segments of the colorectum by way of the serosa, as confirmed on microscopic examination, or for tumours in a retroperiotoneal or subperiotoneal location, direct invasion of other organs or structures by virtue of extension beyond the muscularis propria.</span></p><p class="s117" style="padding-top: 3pt;padding-right: 8pt;text-indent: 0pt;line-height: 109%;text-align: justify;">d <span class="s118">Tumour that is adherent to other organs or structures, macroscopically, is classified cT4b. however, if no other tumour is present in the adhesion, microscopically, the classification should be pT1-3, depending on the anatomical depth of wall invasion.</span></p></td></tr><tr style="height:15pt"><td style="width:323pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9" colspan="2"><p class="s26" style="padding-top: 2pt;text-indent: 0pt;text-align: left;">N regional lymph nodes</p></td></tr><tr style="height:15pt"><td style="width:23pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;text-indent: 0pt;text-align: left;">nX</p></td><td style="width:300pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;padding-left: 9pt;text-indent: 0pt;text-align: left;">regional lymph nodes cannot be assessed</p></td></tr><tr style="height:15pt"><td style="width:23pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;text-indent: 0pt;text-align: left;">n0</p></td><td style="width:300pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;padding-left: 9pt;text-indent: 0pt;text-align: left;">no regional lymph node metastasis</p></td></tr><tr style="height:15pt"><td style="width:23pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;text-indent: 0pt;text-align: left;">n1</p></td><td style="width:300pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;padding-left: 9pt;text-indent: 0pt;text-align: left;">Metastasis in 1–3 regional lymph nodes</p></td></tr><tr style="height:15pt"><td style="width:23pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;text-indent: 0pt;text-align: left;">n1a</p></td><td style="width:300pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;padding-left: 9pt;text-indent: 0pt;text-align: left;">Metastasis in 1 regional lymph node</p></td></tr><tr style="height:15pt"><td style="width:23pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;text-indent: 0pt;text-align: left;">n1b</p></td><td style="width:300pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;padding-left: 9pt;text-indent: 0pt;text-align: left;">Metastasis in 2–3 regional lymph nodes</p></td></tr><tr style="height:26pt"><td style="width:23pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;text-indent: 0pt;text-align: left;">n1c</p></td><td style="width:300pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;padding-left: 9pt;text-indent: 0pt;line-height: 111%;text-align: left;">Tumour deposit(s), that is, satellites*, in the subserosa, or in non-peritonealized peicolic or perirectal soft tissue <i>without </i>regional lymph node metastasis</p></td></tr><tr style="height:15pt"><td style="width:23pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;text-indent: 0pt;text-align: left;">n2</p></td><td style="width:300pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;padding-left: 9pt;text-indent: 0pt;text-align: left;">Metastasis in 4 or more regional lymph nodes</p></td></tr><tr style="height:15pt"><td style="width:23pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;text-indent: 0pt;text-align: left;">n2a</p></td><td style="width:300pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;padding-left: 9pt;text-indent: 0pt;text-align: left;">Metastasis in 4–6 regional lymph nodes</p></td></tr><tr style="height:15pt"><td style="width:23pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;text-indent: 0pt;text-align: left;">n2b</p></td><td style="width:300pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;padding-left: 9pt;text-indent: 0pt;text-align: left;">Metastasis in 7 or more regional lymph nodes</p></td></tr><tr style="height:80pt"><td style="width:323pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9" colspan="2"><p class="s106" style="padding-top: 2pt;text-indent: 0pt;text-align: left;">note</p><p class="s106" style="padding-top: 3pt;padding-right: 8pt;text-indent: 0pt;line-height: 109%;text-align: left;">* Tumour deposits (satellites) are discrete macroscopic or microscopic nodules of cancer in the pericolorectal adipose tissue’s lymph drainage area of a primary carcinoma that are discontinuous from the primary and without histological evidence of residual lymph node or identifiable vascular or neural structures. if a vessel wall is identifiable on h&amp;e, elastic or other stains, it should be classified as venous invasion (V1/2) or lymphatic invasion (l1). similarly, if neural structures are identifiable, the lesion should be classified as perineural invasion</p><p class="s106" style="text-indent: 0pt;line-height: 109%;text-align: left;">(pn1). The presence of tumour deposits does not change the primary tumour T category, but changes the node status (n) to pn1c if all regional lymph nodes are negative on pathological examination.</p></td></tr></table><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s119" style="padding-top: 4pt;padding-left: 11pt;text-indent: 0pt;text-align: right;">(continued)</p><p class="s24" style="padding-top: 5pt;padding-left: 11pt;text-indent: 0pt;text-align: left;">Table 12.1 <span class="s52">Continued</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><table style="border-collapse:collapse;margin-left:11.3622pt" cellspacing="0"><tr style="height:15pt"><td style="width:323pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9" colspan="2"><p class="s26" style="padding-top: 2pt;text-indent: 0pt;text-align: left;">M distant metastasis</p></td></tr><tr style="height:15pt"><td style="width:24pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;text-indent: 0pt;text-align: left;">M0</p></td><td style="width:299pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;padding-left: 8pt;text-indent: 0pt;text-align: left;">no distant metastasis</p></td></tr><tr style="height:15pt"><td style="width:24pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;text-indent: 0pt;text-align: left;">M1</p></td><td style="width:299pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;padding-left: 8pt;text-indent: 0pt;text-align: left;">Distant metastasis</p></td></tr><tr style="height:26pt"><td style="width:24pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;text-indent: 0pt;text-align: left;">M1a</p></td><td style="width:299pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;padding-left: 8pt;text-indent: 0pt;line-height: 111%;text-align: left;">Metastasis confined to one organ (liver, lung, ovary, non-regional lymph node(s)) without peritoneal metastases</p></td></tr><tr style="height:15pt"><td style="width:24pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;text-indent: 0pt;text-align: left;">M1b</p></td><td style="width:299pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;padding-left: 8pt;text-indent: 0pt;text-align: left;">Metastasis in more than one organ</p></td></tr><tr style="height:15pt"><td style="width:24pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;text-indent: 0pt;text-align: left;">M1c</p></td><td style="width:299pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;padding-left: 8pt;text-indent: 0pt;text-align: left;">Metastasis to the peritoneum with or without other organ involvement</p></td></tr><tr style="height:20pt"><td style="width:323pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9" colspan="2"><p class="s106" style="padding-right: 8pt;text-indent: 0pt;line-height: 9pt;text-align: left;">reproduced with permission from sobin lh, gospodarowicz MK, Wittekind Ch. <i>UICC TNM Classification of Malignant Tumours. </i>8th ed. © 2017 Wiley Blackwell.</p></td></tr></table><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s24" style="padding-top: 7pt;padding-left: 85pt;text-indent: 0pt;text-align: left;">Table 12.2 <span class="s52">Duke’s classification</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><table style="border-collapse:collapse;margin-left:85.8622pt" cellspacing="0"><tr style="height:15pt"><td style="width:27pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;text-indent: 0pt;text-align: left;">a</p></td><td style="width:148pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;padding-left: 21pt;text-indent: 0pt;text-align: left;">Tumour confined to bowel wall</p></td></tr><tr style="height:15pt"><td style="width:27pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;text-indent: 0pt;text-align: left;">B</p></td><td style="width:148pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;padding-left: 21pt;text-indent: 0pt;text-align: left;">Tumour penetrates bowel wall</p></td></tr><tr style="height:15pt"><td style="width:27pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;text-indent: 0pt;text-align: left;">C</p></td><td style="width:148pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;padding-left: 21pt;text-indent: 0pt;text-align: left;">regional lymph nodes involved</p></td></tr><tr style="height:15pt"><td style="width:27pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;text-indent: 0pt;text-align: left;">D</p></td><td style="width:148pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;padding-left: 21pt;text-indent: 0pt;text-align: left;">Distant metastases</p></td></tr></table><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 59pt;text-indent: 0pt;text-align: left;"><span><img width="297" height="322" alt="image" src="Image_176.gif"/></span></p><p class="s24" style="padding-top: 7pt;padding-left: 11pt;text-indent: 0pt;line-height: 114%;text-align: left;">Fig. 12.2 <span class="s52">Transaxial oblique T2-weighted Mri showing a T3c rectal cancer with contiguous extramural vascular invasion extending 8mm beyond the hypointense muscularis propria into the mesorectal fat (bold arrow head). The CrM (short arrows) is not threatened as the distance to the CrM (thin straight line) is &gt;1mm.</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 53pt;text-indent: 0pt;text-align: left;"><span><img width="297" height="340" alt="image" src="Image_177.gif"/></span></p><p class="s24" style="padding-top: 7pt;padding-left: 5pt;text-indent: 0pt;line-height: 113%;text-align: left;">Fig. 12.3 <span class="s52">Transrectal us image showing a T2 rectal tumour confined to the muscularis propria (arrow).</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-top: 4pt;padding-left: 14pt;text-indent: 0pt;line-height: 12pt;text-align: justify;">Transrectal ultrasound (TRUS) is preferred for small early tumours (T1N0 or T2N0;</p><p style="padding-left: 5pt;text-indent: 0pt;line-height: 94%;text-align: justify;">&lt;3 cm; within 8 cm of anal verge) to assess if local excision is appropriate. Infiltration of the rectal wall layers by tumour is well demonstrated (Figure 12.3). However, T2 tumours may be overstaged due to peritumoural inflammation and the technique is inferior to MRI for depiction of the potential surgical CRM due to its limited field of view. A meta-analysis examining the accuracy of TRUS, MRI, and CT for local staging has suggested that TRUS has better diagnostic accuracy for perirectal tissue invasion than CT or MRI with sensitivities of 90% vs. 79% and 82%, but comparable accuracy for invasion of adjacent organs (sensitivities of 70–74%).<span class="s22">5</span></p><p class="s65" style="padding-left: 14pt;text-indent: 0pt;line-height: 11pt;text-align: justify;">18<span class="s44">F-fluorodeoxyglucose (</span>18<span class="s44">F-FDG) positron emission tomography (PET)/CT is</span></p><p style="padding-left: 5pt;text-indent: 0pt;line-height: 94%;text-align: justify;">not recommended for initial distant staging. However, it is recommended when CT is equivocal or when synchronous metastases are potentially suitable for resection.<span class="s22">6 </span>Studies on rectal cancer have shown nearly a 30% change in tumour stage or treatment plan on <span class="s22">18</span>F-FDG PET/CT, more frequent for low rectal cancers.<span class="s22">7</span></p><p style="padding-left: 5pt;text-indent: 8pt;line-height: 94%;text-align: justify;">Reliable detection of nodal involvement still remains a challenge for imaging. The majority of histologically involved lymph nodes are &lt;5 mm and will not raise suspi- cion on size criteria alone. Furthermore, many involved nodes are &lt;3 mm and may not be seen on imaging. Accuracies with a variation of 62–83% have been reported for TRUS while accuracies with a variation of 39–95% have been reported for MRI. The use of morphological appearances on high resolution MRI based on the nodal outline</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 59pt;text-indent: 0pt;text-align: left;"><span><img width="297" height="297" alt="image" src="Image_178.gif"/></span></p><p class="s24" style="padding-top: 7pt;padding-left: 11pt;text-indent: 0pt;line-height: 113%;text-align: left;">Fig. 12.4 <span class="s52">T2-weighted coronal oblique image shows an 8 mm mesorectal node (arrow) at 9 o’clock showing an irregular outline and heterogeneous signal, similar to the tumour (star).</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-top: 5pt;padding-left: 11pt;text-indent: 0pt;line-height: 94%;text-align: justify;">and signal intensity are more reliable than size. Nodes are judged suspicious if they have irregular borders, mixed signal intensity, or both (Figure 12.4). FDG PET/CT has also not been shown to be superior to conventional imaging for nodal staging, with sensitivity of only 29%.</p><p style="padding-left: 11pt;text-indent: 8pt;line-height: 94%;text-align: justify;">About 20% of patients will be diagnosed with metastases at initial presentation, the liver, lungs, and peritoneum being the most common sites. CT is the most commonly used imaging modality for distant staging. However, <span class="s22">18</span>F-FDG PET/CT is more sensi- tive than CT (Figure 12.5) and may identify occult disease missed on conventional CT. Several studies have shown the impact of <span class="s22">18</span>F-FDG PET/CT on the management of this subgroup, avoiding futile surgery.</p><p style="padding-left: 11pt;text-indent: 8pt;line-height: 94%;text-align: right;">A meta-analysis of CT, MRI, and <span class="s22">18</span>F-FDG PET staging performance reported per- patient sensitivities of 64.7%, 75.8%, and 94.6% respectively.<span class="s22">8 18</span>F-FDG PET/CT is rou- tinely recommended for restaging patients with recurrence being considered for radical surgery and/or metastatectomy. Additionally, hepatic MRI with diffusion and contrast en- hancement should be performed for patients planned for resection of hepatic metastases. Recurrent disease occurs in one-third of patients, usually within three years of cura- tive surgery; patients with rectal cancer are at a higher risk (11.3%) of local recurrence compared with patients with colon cancer (6.1%). Although pelvic MRI has high ac- curacy for detecting local recurrence, <span class="s22">18</span>F-FDG PET/CT is now recommended for pa- tients with rising tumour markers and/or clinical suspicion of recurrence with normal</p><p style="padding-left: 11pt;text-indent: 0pt;line-height: 12pt;text-align: justify;">or equivocal findings on other imaging.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 11pt;text-indent: 0pt;text-align: left;"><span><img width="409" height="252" alt="image" src="Image_179.jpg"/></span></p><p class="s52" style="padding-top: 6pt;padding-left: 5pt;text-indent: 0pt;line-height: 113%;text-align: left;"><span class="s24">Fig. 12.5 </span>right rectus abdominis metastasis (long arrow) and a mesorectal deposit (short arrow) are easily identified on the axial <span class="s102">18</span>F-FDg peT/CT images as increased uptake compared to the conventional CT.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s96" style="padding-top: 7pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">12.3 <span class="h4">Imaging for radiotherapy</span></p><p style="padding-top: 4pt;padding-left: 5pt;text-indent: 0pt;line-height: 94%;text-align: justify;">Preoperative RT may be delivered as: (1) short-course RT only; (2) long-course RT with concurrent chemotherapy. A preoperative approach reduces the risk of tu- mour seeding, increases the likelihood of an R0 resection, has less acute toxicity and enhanced radiosensitivity due to better oxygenated cells, and is favoured in the UK. Postoperative treatment is rarely used and has been shown to be inferior in a large RCT.</p><p style="padding-left: 5pt;text-indent: 8pt;line-height: 94%;text-align: justify;">Short-course radiotherapy (SCRT) is 25 Gy in five daily fractions and long-course radiotherapy is commonly 45 Gy in 25 daily fractions or 50.4 Gy in 28 daily fractions. This is typically given with concurrent fluoropyrimidine chemotherapy (LCCRT).</p><p class="s97" style="padding-top: 10pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">12.3.1 <span class="s29">Treatment planning</span></p><p style="padding-top: 3pt;padding-left: 5pt;text-indent: 0pt;line-height: 94%;text-align: justify;">Individualized CT-based volume definition is superior to the previously used field- based planning technique. The individualized planning CT is performed from the su- perior aspect of L5 to 2 cm beyond the anal margin, which may be defined by an anal marker placed prior to the CT scan. Images ≤3 mm slice thickness are acquired. Oral dilute gastrograffin or barium contrast to opacify the bowel, and intravenous contrast to highlight vessels, and delayed imaging for ureteric opacification is recommended. Patients may be scanned supine or prone. A full bladder and the use of special immo- bilization devices such as the ‘belly board’ can reduce the volume of small-bowel in the pelvis, thus reducing both acute- and long-term toxicity.</p><p style="padding-left: 5pt;text-indent: 8pt;line-height: 94%;text-align: justify;">The radiotherapy volume should encompass the gross tumour in terms of primary and discontinuous spread, the lymph nodes that are suspected of being involved, and</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 17pt;text-indent: 0pt;text-align: left;"><span><img width="409" height="268" alt="image" src="Image_180.gif"/></span></p><p class="s24" style="padding-top: 6pt;padding-left: 11pt;text-indent: 0pt;line-height: 113%;text-align: left;">Fig. 12.6 <span class="s52">planning CT demonstrating definition of gTV, CTV expanded, CTV2, and pTV for a mid-rectal cancer from its superior to inferior aspect.</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-top: 5pt;padding-left: 11pt;text-indent: 0pt;line-height: 94%;text-align: justify;">potential areas of microscopic spread. The gross tumour volume (GTV) includes the visible tumour and involved lymph nodes, which is then expanded by 1 cm in all dir- ections to create the clinical target volume (CTV). The final planning target volume (PTV) is then obtained by expanding the CTV in all directions, typically, by 1 cm. The PTV allows for inter-fraction organ displacement and set-up errors.</p><p style="padding-left: 11pt;text-indent: 8pt;line-height: 94%;text-align: justify;">The volumes and expansions used currently are based on data from previous and current phase III trials, patterns of spread, and local failure. However, different philosophies towards defining the treatment volumes remain. The main thrust of research and development in this field is towards achieving smaller treatment vol- umes by more accurate imaging for treatment planning along with image-guided radiotherapy (IGRT) to minimize the volume of irradiated normal tissues whilst still accurately treating the target volume. The ultimate aim is to increase the therapeutic ratio.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s96" style="padding-left: 11pt;text-indent: 0pt;text-align: left;">12.4 <span class="h4">Therapeutic assessment and follow-up</span></p><p class="s97" style="padding-top: 6pt;padding-left: 11pt;text-indent: 0pt;text-align: left;">12.4.1 <span class="s29">Therapeutic assessment</span></p><p style="padding-top: 3pt;padding-left: 11pt;text-indent: 0pt;line-height: 94%;text-align: justify;">A number of radiation-induced tissue changes including oedema, inflammation, necrosis, and fibrosis may make post-neoadjuvant therapy assessment challenging. However, MRI is most commonly performed. Response to neoadjuvant therapy may be assessed by an MRI tumour regression grade (TRG, Table 12.3)),<span class="s22">4 </span>akin to pathology, where MRI signal intensity changes of the whole tumour are evaluated, including extramural disease and areas of vascular invasion, whether contiguous or</p><p class="s24" style="padding-top: 5pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">Table 12.3 <span class="s52">Mri tumour regression grading</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 5pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="427" height="1" alt="image" src="Image_181.png"/></span></p><p class="s39" style="padding-bottom: 2pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">Grade  Description</p><p style="padding-left: 5pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="427" height="1" alt="image" src="Image_182.png"/></span></p><p class="s54" style="padding-left: 5pt;text-indent: 0pt;line-height: 14pt;text-align: left;">grade 1  Complete radiological response (linear scar only), no evidence of treated tumour grade 2  good response (dense hypointense fibrosis, no obvious tumour signal) signifying</p><p style="text-indent: 0pt;text-align: left;"><span><img width="431" height="1" alt="image" src="Image_183.png"/></span></p><p class="s54" style="padding-bottom: 3pt;padding-left: 48pt;text-indent: 0pt;line-height: 9pt;text-align: left;">no tumour or minimal residual disease</p><p style="padding-left: 5pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="433" height="1" alt="image" src="Image_184.png"/></span></p><p class="s54" style="padding-top: 1pt;padding-bottom: 2pt;padding-left: 48pt;text-indent: -42pt;line-height: 111%;text-align: left;">grade 3  Moderate response (&gt;50% fibrosis or mucin and visible intermediate signal intensity) signifying residual tumour</p><p style="padding-left: 5pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="433" height="1" alt="image" src="Image_185.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><span><img width="431" height="1" alt="image" src="Image_186.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><span><img width="431" height="1" alt="image" src="Image_187.png"/></span></p><p class="s54" style="padding-top: 1pt;padding-left: 5pt;text-indent: 0pt;line-height: 161%;text-align: left;">grade 4  Minimal response (mostly tumour, minimal fibrosis/mucinous degeneration) grade 5  no response in the primary tumour or frank tumour progression</p><p class="s14" style="padding-left: 5pt;text-indent: 0pt;line-height: 7pt;text-align: left;">source: data from 1) patel uB, et al. ‘Mri after treatment of locally advanced rectal cancer: how to report</p><p class="s14" style="padding-left: 5pt;text-indent: 0pt;line-height: 109%;text-align: left;">tumor response-The MerCury experience’. <i>American Journal of Roentgenology </i>(2012), Vol. 199, issue 4, pp.W486–W9, and 2) Mandard aM, et al. ‘pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma’. <i>Cancer </i>(1994), Vol. 73, issue 11, pp.2680–2686.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-top: 5pt;padding-left: 5pt;text-indent: 0pt;line-height: 94%;text-align: justify;">not (Figure 12.7). Tumour regression grading is a better predictor of outcome after treatment than T stage.<span class="s22">9</span></p><p style="padding-left: 5pt;text-indent: 8pt;line-height: 94%;text-align: justify;">Currently, MRI is recommended 8–10 weeks after the completion of treatment. However, the optimum timing is not established, and this remains a clinical decision. Some clinicians prefer to scan 12 weeks post treatment. This is based on studies which demonstrate that the volume-halving time for rectal cancers is 14 days. Thus, the time for an average tumour to regress to &lt;0.1 cm<span class="s22">3 </span>is about 15 weeks post CRT. However, there is no evidence that such a delayed assessment and subsequent surgery improves cancer-specific or overall survival and there are concerns about an increase in resec- tion margin positivity with a delayed approach.<span class="s22">10</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="text-indent: 0pt;text-align: left;"><span><img width="416" height="207" alt="image" src="Image_188.gif"/></span></p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(a)</p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(a)</p><p style="text-indent: 0pt;text-align: left;"/><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(a)</p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(b)</p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(b)</p><p style="text-indent: 0pt;text-align: left;"/><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(b)</p><p class="s24" style="padding-top: 3pt;padding-left: 5pt;text-indent: 0pt;line-height: 114%;text-align: left;">Fig. 12.7 <span class="s52">T2-weighted coronal Mr images. There is a low rectal tumour seen with intermediate signal (* in (a)). Follow up three months post CrT shows moderate response with both low signal fibrosis (sold arrow in (b) and intermediate signal residual tumour (dotted arrow in (b) scored as mrTrg 3.</span></p><p style="padding-top: 4pt;padding-left: 11pt;text-indent: 8pt;line-height: 94%;text-align: justify;">Identification of a complete response is best done with a combination of digital rectal examination (DRE), endoscopy, and MRI (for nodal regression). Typically a flat white scar is seen on endoscopy, with only signs of fibrosis and complete nodal re- gression on MRI.<span class="s22">11 </span>The value of additional <span class="s22">18</span>F-FDG PET/CT is still unclear and not routinely recommended.</p><p class="s97" style="padding-top: 10pt;padding-left: 11pt;text-indent: 0pt;text-align: left;">12.4.2 <span class="s29">Surveillance</span></p><p style="padding-top: 3pt;padding-left: 11pt;text-indent: 0pt;line-height: 94%;text-align: justify;">There has been debate over the best approach for surveillance. An American Society of Clinical Oncology expert panel concluded that periodic clinical evaluation with carcinoembryonic antigen (CEA) and colonoscopy were justifiable, but other testing added little benefit. Randomized trials of more intensive versus less intensive strat- egies have been difficult to conduct. Older trials, mainly from the 1990s, have included colon and rectal cancers, early to advanced stage, less well-defined indi- cations for adjuvant therapy, and differing frequency and type of screening for in- tensive and less intensive groups. Results from these studies have suggested that the number of recurrences is similar for either group, but are detected earlier with more intensive surveillance. More recent trials and a recently published meta-analysis<span class="s22">12 </span>suggest an improvement in overall survival with more intense follow-up regimes and an improvement in cancer specific survival in patients who have more tests as compared to those who have fewer tests. However, these studies included colon and rectal cancer patients and are heterogeneous and used very different follow-up schedules, tests, and duration of follow-up.</p><p style="padding-left: 19pt;text-indent: 0pt;line-height: 11pt;text-align: justify;">In patients who have an initial complete response and remain on active surveillance,</p><p style="padding-left: 11pt;text-indent: 0pt;line-height: 94%;text-align: justify;">this should focus on early detection and treatment of regrowth. Although a uniform protocol has not yet been established, expert opinion favours intensive surveillance with DRE, flexible endoscopy, and MRI including diffusion in the first two years,<span class="s22">13 </span>and decreasing intensity in subsequent years.<span class="s22">14 </span>In practice, three- or six-monthly CEA tests and yearly body CT scans are commonly performed for surveillance for at least three years in the UK, but clearly further clarification is needed.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s96" style="padding-left: 11pt;text-indent: 0pt;text-align: left;">12.5 <span class="h4">Summary</span></p><p class="s23" style="padding-top: 6pt;padding-left: 23pt;text-indent: -11pt;line-height: 94%;text-align: justify;">◆ <span class="p">MRI is the modality of choice for locoregional staging and assessment of potential resectability.</span></p><p style="padding-top: 2pt;padding-left: 23pt;text-indent: -11pt;line-height: 94%;text-align: justify;"><span class="s23">◆ </span>CT is performed for staging metastatic disease; however, <span class="s22">18</span>F-FDG PET/CT is more sensitive and may play a greater role in the future, particularly if surgical excision of oligometastatic disease is being considered.</p><p style="padding-top: 2pt;padding-left: 23pt;text-indent: -11pt;line-height: 94%;text-align: justify;"><span class="s23">◆ </span>RT planning using CT has limitations that CT/MRI fusion, <span class="s22">18</span>F-FDG PET/CT, or MRI planning may overcome, but these techniques require further validation.</p><p class="s23" style="padding-top: 2pt;padding-left: 23pt;text-indent: -11pt;line-height: 94%;text-align: justify;">◆ <span class="p">MRI is the preferred modality for assessing neoadjuvant therapy, typically at 8–10 weeks following completion.</span></p><p class="s23" style="padding-top: 2pt;padding-left: 23pt;text-indent: -11pt;line-height: 94%;text-align: justify;">◆ <span class="p">Debate continues as to the optimum method for surveillance. Yearly body CT is advocated currently.</span></p><p class="s73" style="padding-top: 5pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">References</p><p class="s74" style="padding-top: 5pt;padding-left: 20pt;text-indent: -9pt;text-align: left;">1. <b>Renehan A</b>, <b>Malcomson L</b>, <b>Emsley R, et al. </b>(2016). Watch-and-wait approach versus surgical resection after chemoradiotherapy for patients with rectal cancer (the OnCoRe project). <i>Lancet</i>, <b>17</b>(2): 174–183.</p><p class="s74" style="padding-top: 1pt;padding-left: 20pt;text-indent: -9pt;text-align: left;">2. <b>Cunningham C</b>, <b>Leong K</b>, <b>Clark S, et al. </b>(2017). Association of Coloproctology of Great Britain &amp; Ireland (ACPGBI): Guidelines for the Management of Cancer of the Colon, Rectum and Anus (2017)—Diagnosis, Investigations and Screening. <i>Colorectal Disease</i>, <b>19</b>(Suppl. 1): 9–17.</p><p class="s74" style="padding-top: 1pt;padding-left: 20pt;text-indent: -9pt;text-align: left;">3. <b>Mercury Study Group </b>(2006). Diagnostic accuracy of preoperative magnetic resonance imaging in predicting curative resection of rectal cancer: prospective observational study. <i>British Medical Journal</i>, <b>333</b>: 779–784.</p><p class="s74" style="padding-top: 1pt;padding-left: 20pt;text-indent: -9pt;text-align: left;">4. <b>Patel UB</b>, <b>Blomqvist LK</b>, <b>Taylor F, et al. </b>(2012). MRI after treatment of locally advanced rectal cancer: how to report tumor response—the MERCURY experience. <i>American Journal of Roentgenology</i>, <b>199</b>(4): W486–W489.</p><p class="s74" style="padding-top: 1pt;padding-left: 20pt;text-indent: -9pt;text-align: left;">5. <b>Bipat S</b>, <b>Glas AS</b>, <b>Slors FJM, et al. </b>(2004). Rectal cancer: local staging and assessment of lymph node involvement with endoluminal US, CT and MR imaging-a meta-analysis. <i>Radiology</i>, <b>232</b>: 773–783.</p><p class="s74" style="padding-top: 1pt;padding-left: 20pt;text-indent: -9pt;text-align: left;">6. <b>Evidence-based indications for the use of PET-CT in the United Kingdom </b><a href="https://www.rcr.ac.uk/publication/evidence-based-indications-use-pet-ct-united-kingdom-2016" class="a" target="_blank">(2016). London: The Royal College of Radiologists. https://www.rcr.ac.uk/publication/evidence- </a>based-indications-use-pet-ct-united-kingdom-2016 (accessed 11 January 2021).</p><p class="s74" style="padding-top: 1pt;padding-left: 20pt;text-indent: -9pt;text-align: left;">7. <b>Petersen RK</b>, <b>Hess S</b>, <b>Alavi A</b>, <b>Hoilund-Carlsen PF </b>(2014). Clinical impact of FDG-PET/ CT on colorectal cancer staging and treatment strategy. <i>American Journal of Nuclear Medicine Molecular Imaging</i>, <b>4</b>(5): 471–482.</p><p class="s74" style="padding-top: 1pt;padding-left: 20pt;text-indent: -9pt;text-align: left;">8. <b>Bipat S</b>, <b>van Leeuwen MS</b>, <b>Comans EF, et al. </b>(2005). Colorectal liver metastases: CT, MR imaging, and PET for diagnosis—meta-analysis. <i>Radiology</i>, <b>237</b>(1): 123–131.</p><p class="s74" style="padding-top: 1pt;padding-left: 20pt;text-indent: -9pt;text-align: justify;">9. <b>Taylor FG</b>, <b>Swift RI</b>, <b>Blomqvist L</b>, <b>Brown G </b>(2008). A systematic approach to the interpretation of preoperative staging MRI for rectal cancer. <i>American Journal of Roentgenology</i>, <b>191</b>: 1827–1835.</p><p class="s74" style="padding-top: 1pt;padding-left: 20pt;text-indent: -13pt;text-align: justify;">10. <b>Sclafani F </b>and <b>Chau I </b>(2016). Timing of therapies in the multidisciplinary treatment of locally advanced rectal cancer: available evidence and implications for routine practice. <i>Seminars in Radiation Oncology</i>, <b>26</b>(3): 176–185.</p><p class="s74" style="padding-top: 1pt;padding-left: 20pt;text-indent: -13pt;text-align: left;">11. <b>Maas M</b>, <b>Lambregts DM</b>, <b>Nelemans PJ, et al. </b>(2015). Assessment of clinical complete response after chemoradiation for rectal cancer with digital rectal examination, endoscopy, and MRI: selection for organ-saving treatment. <i>Annals of Surgical Oncology</i>, <b>22</b>: 3873–3880.</p><p class="s74" style="padding-top: 1pt;padding-left: 20pt;text-indent: -13pt;text-align: left;">12. <b>Jeffery M</b>, <b>Hickey BE</b>, <b>Hider PN</b>, <b>See AM </b>(2016). Follow-up strategies for patients treated for non-metastatic colorectal cancer. <i>Cochrane Database Systematic Reviews</i>, <b>11</b>(11): CD002200.</p><p class="s74" style="padding-top: 1pt;padding-left: 20pt;text-indent: -13pt;text-align: left;">13. <b>Lambregts DM</b>, <b>Lahaye MJ</b>, <b>Heijnen LA, et al. </b>(2016). MRI and diffusion-weighted MRI to diagnose a local tumour regrowth during long-term follow-up of rectal cancer patients treated with organ preservation after chemoradiotherapy. <i>European Radiology</i>, <b>26</b>: 2118–2125.</p><p class="s74" style="padding-top: 1pt;padding-left: 20pt;text-indent: -13pt;text-align: justify;">14. <b>Van der Valk MJM</b>, <b>Hilling DE</b>, <b>Bastiaannet E, et al., and the IWWD Consortium </b>(2018). Long-term outcomes of clinical complete responders after neoadjuvant treatment for rectal cancer in the International Watch &amp; Wait Database (IWWD): an international multicentre registry study. <i>Lancet</i>, <b>391</b>: 2537–2545.</p><p class="nav">&nbsp;&nbsp;</p><p class="nav">&nbsp;</p><p class="nav"><a href="part17.htm">&lt; Назад</a><span> | </span><a href="../index.html">Содержимое</a><span> | </span><a href="part19.htm">Далее &gt;</a></p><p class="nav">&nbsp;&nbsp;</p></body></html>
